Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome. NAFLD encompasses a wide histological spectrum ranging from benign simple steatosis to non-alcoholic steatohepatitis (NASH). Sustained inflammation in the liver is critical in this process. Hepatic macrophages, including liver resident macropaghes (Kupffer cells), monocytes infiltrating the injured liver, as well as specific lymphocytes subsets play a pivotal role in the initiation and perpetuation of the inflammatory response, with a major deleterious impact on the progression of fatty liver to fibrosis. During the last years, Th17 cells have been involved in the development of inflammation not only in liver but also in other organs, such as adipose tissue or lung. Differentiation of a naïve T cell into a Th17 cell leads to pro-inflammatory cytokine and chemokine production with subsequent myeloid cell recruitment to the inflamed tissue. Th17 response can be mitigated by T regulatory cells that secrete anti-inflammatory cytokines. Both T cell subsets need TGF-β for their differentiation and a characteristic plasticity in their phenotype may render them new therapeutic targets. In this review, we discuss the role of the Th17 pathway in NAFLD progression to NASH and to liver fibrosis analyzing different animal models of liver injury and human studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092121 · Cited by 730
Meng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711
Rau, M., Schilling, A.-K., Meertens, J., Hering, I., Weiss, J., Jurowich, C., Kudlich, T., Hermanns, H. M., Bantel, H., Beyersdorf, N., et al. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1501175 · Cited by 302
Kang, Z., Altuntas, C. Z., Gulen, M. F., Liu, C., Giltiay, N., Qin, H., Liu, L., Qian, W., Ransohoff, R. M., Bergmann, C., et al. (2010) · Immunity · doi:10.1016/j.immuni.2010.03.004 · Cited by 297
Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease
Tang, Y., Bian, Z., Zhao, L., Liu, Y., Liang, S., Wang, Q., Han, X., Peng, Y., Chen, X., Shen, L., et al. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04471.x · Cited by 294
Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production
Ogata, H., Chinen, T., Yoshida, T., Kinjyo, I., Takaesu, G., Shiraishi, H., Iida, M., Kobayashi, T., & Yoshimura, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209281 · Cited by 246
IL-1 and IL-23 Mediate Early IL-17A Production in Pulmonary Inflammation Leading to Late Fibrosis
Gasse, P., Riteau, N., Vacher, R., Michel, M.-L., Fautrel, A., di Padova, F., Fick, L., Charron, S., Lagente, V., Eberl, G., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023185 · Cited by 208
Pathophysiology of NASH: perspectives for a targeted treatment
Marra, F., & Lotersztajn, S. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990344 · Cited by 163
Rolla, S., Alchera, E., Imarisio, C., Bardina, V., Valente, G., Cappello, P., Mombello, C., Follenzi, A., Novelli, F., & Carini, R. (2016) · Clinical Science · doi:10.1042/cs20150405 · Cited by 158
Fabre, T., Kared, H., Friedman, S. L., & Shoukry, N. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400861 · Cited by 150
Cited by
Schwimmer, J. B., Johnson, J. S., Angeles, J. E., Behling, C., Belt, P. H., Borecki, I., Bross, C., Durelle, J., Goyal, N. P., Hamilton, G., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.06.028 · Cited by 298
Immunomodulatory Role of the Extracellular Matrix Within the Liver Disease Microenvironment
McQuitty, C. E., Williams, R., Chokshi, S., & Urbani, L. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.574276 · Cited by 146
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Sawada, K., Chung, H., Softic, S., Moreno-Fernandez, M. E., & Divanovic, S. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.10.009 · Cited by 139
Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems
Ross, T. T., Crowley, C., Kelly, K. L., Rinaldi, A., Beebe, D. A., Lech, M. P., Martinez, R. V., Carvajal-Gonzalez, S., Boucher, M., Hirenallur-Shanthappa, D., et al. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.06.001 · Cited by 94
Zhang, H., Ma, Y., Cheng, X., Wu, D., Huang, X., Chen, B., Ren, Y., Jiang, W., Tang, X., Bai, T., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1206 · Cited by 65
Metadata
- Authors
- Chackelevicius, C. M., Gambaro, S. E., Tiribelli, C., & Rosso, N.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2016
- Volume
- 22
- Issue
- 41
- Pages
- 9096
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2548517585
- Cited by
- 57
- References
- 13
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. https://app.cochat.ai/papers/10.3748/wjg.v22.i41.9096
- The paper
- Chackelevicius, C. M., Gambaro, S. E., Tiribelli, C., & Rosso, N. (2016). Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis. World Journal of Gastroenterology. https://doi.org/10.3748/wjg.v22.i41.9096
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.